SNORD22: A Non-Coding RNA Molecule Regulating Gene Expression in Eukaryotic Cells

Target Name: SNORD22

NCBI ID: G9304

SNORD22

Other Name(s): Small nucleolar RNA, C/D box 22 | RNU22 | small nucleolar RNA, C/D box 22 | U22

SNORD22: A Non-Coding RNA Molecule Regulating Gene Expression in Eukaryotic Cells

SNORD22, also known as Small Nucleolar RNA (snRNA), is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. It is composed of 22 amino acid residues and has a characteristic C/D box structure.

SNORD22 is a key regulator of gene expression and has been implicated in a wide range of cellular processes, including DNA replication, transcription, and translation. It is a part of a complex RNA regulatory network that includes other non-coding RNAs, such as microRNAs and long non-coding RNAs, as well as proteins that interact with them to regulate gene expression.

SNORD22 has been shown to play a role in the regulation of gene expression in various organisms, including humans. Studies have identified SNORD22 as a potential drug target and have suggested that inhibiting its activity may be a useful therapeutic approach for a variety of diseases.

One of the key challenges in studying SNORD22 is its complex regulatory network. Because it affects so many different gene expressions, it is difficult to determine whether it acts by directly binding to DNA or by affecting RNA-binding proteins (RBPs). . However, research shows that SNORD22 regulates gene expression by binding to DNA.

The role of SNORD22 in the gene expression regulatory network is to regulate gene expression by binding to DNA. It can bind to the DNA of certain genes, thereby affecting the transcription of these genes. It can also bind to the RNA of certain genes, thereby affecting the translation of these genes. These processes are completed by the binding protein (BP) of SNORD22.

BP is a protein that binds to the C/D box of SNORD22. The binding of BP will cause conformational changes in the C/D box of SNORD22, thereby affecting the binding of RNA-binding protein (RBP). RBP is a protein that binds to the C/D box of SNORD22 to regulate gene expression.

Therefore, the C/D box of SNORD22 is a key part of its gene expression regulatory network. Studying the C/D box structure of SNORD22 is very important to understand its role in gene expression regulation.

In recent years, researchers have continued to study SNORD22 in depth and found that it plays an important role in many diseases. For example, research shows that SNORD22 plays an important role in Alzheimer's disease because it regulates the production of amyloid, one of the most commonly detected proteins in Alzheimer's patients.

In addition, SNORD22 has been linked to many other diseases. For example, studies have shown that SNORD22 plays an important role in Parkinson's disease because it regulates neuronal apoptosis, which occurs more in Parkinson's disease patients.

Therefore, SNORD22 is a promising drug target. Studying the structure and function of SNORD22 and developing new drugs can provide us with better treatment options and thus improve patient health.

Protein Name: Small Nucleolar RNA, C/D Box 22

The "SNORD22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets